Sunday, October 24, 2021

India-based CDMO Piramal sketches out $32M upgrade to Michigan drug ingredient facility


Another year, another expansion: After wrapping improvements on a Michigan API facility in 2019, Indian CDMO Piramal Pharma Solutions is at it again, laying plans for a second upgrade.

Piramal will invest some $32 million into its manufacturing plant in Riverview, Michigan, shoring up production and development for potent and non-potent active pharmaceutical ingredients (APIs) over the next two years.

Sponsored by Clinical Ink

Deploy Configurable, Fit-for-Purpose ePRO Solutions, Fast.

Clinical Ink’s enhanced Lunexis™ ePRO+ module streamlines processes through a flexible, unified platform that allows patients and sites a high degree of optionality.

The more than 25,000-square-foot expansion will add 8,500 square feet of production space. It’s also expected to boost capacity for large-scale manufacturing, thanks to new bioreactors that can handle projects up to 4,000 liters, the CDMO said in a release (PDF).

When all is said and done, the expansion is expected to boost API production there by 30% to 40%, a Piramal spokesperson said over email.

Work on the facility is set to wrap in summer 2022 and will see the company recruit around 20 new hires, growing the total Riverview workforce to more than 180 employees, Piramal said.

RELATED: Piramal CDMO closes in on private equity deal to raise up to $500M: report

Alongside production space, Piramal is adding two new kilo labs—smaller setups used to test production with new methods or of new products—for process development and clinical supply at scales up to 100 liters.

As for the two new bioreactors, the CDMO has picked a 3,000-liter/4,000-liter mild-steel glass-lined reactor and a 3,000-liter Hastelloy reactor. Both can make high-potency APIs with occupational exposure limits greater than 1mcg/m3, Piramal said.

This marks the CDMO’s second Riverview upgrade in as many years, beefing up a facility its parent company bought from Ash Stevens in 2016.

In 2019, the company wrapped a $10 million expansion at the site, bringing on two kilo laboratories, plus quality control and analysis labs. The expansion opened the company’s doors to a new set of customers, including those in the antibody-drug conjugate business, Piramal said at the time.

RELATED: M&A-minded Piramal near $500M deal to sell pharma stake to KKR: report

In June, the company made another play at boosting U.S. operations when it picked up a former G&W Laboratories oral solid-dose plant in Sellersville, Pennsylvania. The company will use that site to increase its tablet and capsule offerings, though the Sellersville facility can also pump out creams, ointments and oral liquids, Piramal said.

Meanwhile, the CDMO’s parent company, Piramal Pharma, announced in June that Washington, D.C.-based The Carlyle Group would acquire a 20% stake in the company, bagging Piramal around $490 million for future expansion plans. Once the deal closes, Piramal will consolidate all its pharma units under the Piramal Pharma brand, including its CDMO.



Source link

Latest Articles

Widely used chemical linked to 1,00,000 US deaths per year: Study

NEW YORK: Daily exposure to phthalates, a group of chemicals used in everything from plastic containers to makeup, may lead to approximately 100,000 deaths...

Foods to Reduce Inflammation and Strengthen the Immune System

Did you know that you can greatly reduce inflammation and boost your immune system by simply incorporating more anti-inflammatory foods and beverages into your...

Personal Selling

INTRODUCTION Early sellers and traders were not held in high esteem. The Roman word for salesman meant ‘Cheater’ and...

Building Muscle on a Vegan Diet

There are a lot of  misconceptions surrounding veganism. The notion that those who practice it are lacking in protein and therefore muscles is the...

Electrodes in brain new hope for severe cases of epilepsy

Neurosurgeons at All India Institute of Medical Sciences have devised a new technique for operating on children suffering from a severe form of epilepsy...